Adam Steinlauf (@adams1002) 's Twitter Profile
Adam Steinlauf

@adams1002

I am a specialist in the Inflammatory Bowel Diseases (IBD), Ulcerative Coltitis and Crohn's Disease @ Mount Sinai

ID: 173620615

calendar_today01-08-2010 23:18:46

714 Tweet

617 Followers

1,1K Following

Mount Sinai Division of Gastroenterology (@mountsinaigi) 's Twitter Profile Photo

As we wrap up a day filled with revealing talks and diverse viewpoints on #IBD, at the center of every discussion was one core message: patient #qualityoflife is always the priority. Thanks to all who presented and attended today's event. Looking forward to next year's course!

As we wrap up a day filled with revealing talks and diverse viewpoints on #IBD, at the center of every discussion was one core message: patient #qualityoflife is always the priority. Thanks to all who presented and attended today's event. Looking forward to next year's course!
Adam Steinlauf (@adams1002) 's Twitter Profile Photo

The CCF is committed to supporting patients and families who suffer from IBD and finding a cure for these diseases. Please join me as this years Humanitarian Award recipient in supporting this great organization. fundraiser.onecause.com/fundraiser/org…

Adam Steinlauf (@adams1002) 's Twitter Profile Photo

Our review article for the ACG FDA-related Matters Committee. Overview of biosimilars in inflammatory bowel diseases : Official journal of the American College of Gastroenterology | ACG journals.lww.com/ajg/Abstract/9…

Adam Steinlauf (@adams1002) 's Twitter Profile Photo

I’m excited to be this years Crohn’s & Colitis Foundation Rosenthal Humanitarian Award recipient. Please join me in supporting this important organization!! crohnscolitisfoundation.org/events/56th-an…

Icahn School of Medicine at Mount Sinai (@icahnmountsinai) 's Twitter Profile Photo

Dr. Marla Dubinsky discusses a study that showed the efficacy of Mirikizumab in patients with ulcerative colitis, highlighting its durability via [email protected], which led to the approval of Mirikizumab by the FDA: mshs.co/3QUEo8Q Mount Sinai IBD Center Mount Sinai Department of Medicine

Dr. Marla Dubinsky discusses a study that showed the efficacy of Mirikizumab in patients with ulcerative colitis, highlighting its durability via <a href="/medresearchnews/">info@medicalresearch.com</a>, which led to the approval of Mirikizumab by the FDA: mshs.co/3QUEo8Q

<a href="/MSHS_IBDCenter/">Mount Sinai IBD Center</a> <a href="/DOMSinaiNYC/">Mount Sinai Department of Medicine</a>
Mount Sinai Department of Medicine (@domsinainyc) 's Twitter Profile Photo

Congratulations to Adam Steinlauf, MD, for receiving the prestigious 2023 Rosenthal Humanitarian of the Year Award from the Crohn's & Colitis Foundation. Thank you for your incredible contributions to the #IBD community, Dr. Steinlauf. Crohn's & Colitis Foundation Mount Sinai Division of Gastroenterology #IBDAdvocacy

Congratulations to Adam Steinlauf, MD, for receiving the prestigious 2023 Rosenthal Humanitarian of the Year Award from the Crohn's &amp; Colitis Foundation. Thank you for your incredible contributions to the #IBD community, Dr. Steinlauf. <a href="/CrohnsColitisFn/">Crohn's & Colitis Foundation</a> <a href="/MountSinaiGI/">Mount Sinai Division of Gastroenterology</a> #IBDAdvocacy
Mount Sinai IBD Center (@mshs_ibdcenter) 's Twitter Profile Photo

Are you interested in participating in a clinical trial for Inflammatory Bowel Disease? If so, please fill out the following survey. urldefense.proofpoint.com/v2/url?u=https…

Mount Sinai IBD Center (@mshs_ibdcenter) 's Twitter Profile Photo

If you suffer from IBD and your disease is difficult to control, or if you simply want to be involved in research that will change how we manage IBD, please feel free to fill out the following questionnaire to see if you qualify for a Mount Sinai trial: urldefense.proofpoint.com/v2/url?u=https…